← runs
CVS
CVS HEALTH Corpeval run10-K for period ending 2025-12-31gpt-6-luna@none · prompt v4$0.00062.5s11/11 correct vs SECfiling on sec.gov ↗
figures
| field | value | statement row | printed | SEC |
|---|---|---|---|---|
| Total revenue | $402.1B | R7 Total revenues | 402,067 millions | $402.1B ✓ |
| Operating income | $4.7B | R16 Operating income | 4,660 millions | $4.7B ✓ |
| Net income attributable to the company | $1.8B | R25 Net income attributable to CVS Health | 1,768 millions | $1.8B ✓ |
| Diluted EPS | $1.39 | R28 Diluted | 1.39 | $1.39 ✓ |
| Cash and cash equivalents | $8.5B | R3 Cash and cash equivalents | 8,453 millions | $8.5B ✓ |
| Total assets | $253.5B | R16 Total assets | 253,538 millions | $253.5B ✓ |
| Total liabilities | $178.2B | R33 Total liabilities | 178,156 millions | $178.2B ✓ |
| Total shareholders' equity attributable to the company | $75.2B | R41 Total CVS Health shareholders’ equity | 75,214 millions | $75.2B ✓ |
| Net cash from operating activities | $10.6B | R10 Net cash provided by operating activities | 10,639 millions | $10.6B ✓ |
| Net cash from investing activities | -$5.9B | R17 Net cash used in investing activities | (5,871) millions | -$5.9B ✓ |
| Net cash from financing activities | -$4.9B | R29 Net cash provided by (used in) financing activities | (4,940) millions | -$4.9B ✓ |
checks
- assets = liabilities + equity · total assets equals total liabilities and equity
- equity excludes minority interests · totalEquity excludes noncontrolling interests
- net income is before preferred dividends · net income is not the after-preferred-dividends line
- diluted EPS is for total net income · diluted EPS is for total net income
- net income excludes minority interests · netIncome excludes noncontrolling interests
- cash flows tie to the change in cash · operating + investing + financing (+ FX) equals the net change in cash
trace
0locator (code)0.22s
{ "tables": 121, "exhibits": [], "documents": 1 }{ "income": { "rows": 32, "scale": 1000000, "score": 51.75, "heading": "92 Index to Consolidated Financial Statements Consolidated Statements of Operations", "tableIndex": 26, "runnerUpScore": 25.75 }, "balance": { "rows": 45, "scale": 1000000, "score": 54.75, "heading": "ng notes to consolidated financial statements. 94 Index to Consolidated Financial Statements Consolidated Balance Sheets", "tableIndex": 28, "runnerUpScore": 21.5 }, "cashflow": { "rows": 33, "scale": 1000000, "score": 52.25, "heading": "o consolidated financial statements. 95 Index to Consolidated Financial Statements Consolidated Statements of Cash Flows", "tableIndex": 29, "runnerUpScore": 10 } }1cash flow agent1.71s · 1415 tokens · $0.0002
{ "rows": 33, "retryHint": null, "tableIndex": 29 }{ "figures": [ { "note": "This is the operating activities section total, after all operating cash flows.", "field": "operatingCashFlow", "scale": 1000000, "value": 10639000000, "printed": "10,639", "rowIndex": 10, "rowLabel": "Net cash provided by operating activities", "priorValue": 9107000000, "agentPrinted": "10,639", "failedChecks": [], "priorPrinted": "9,107", "groundingMismatch": false }, { "note": "This is the investing activities section total.", "field": "investingCashFlow", "scale": 1000000, "value": -5871000000, "printed": "(5,871)", "rowIndex": 17, "rowLabel": "Net cash used in investing activities", "priorValue": -7613000000, "agentPrinted": "(5,871)", "failedChecks": [], "priorPrinted": "(7,613)", "groundingMismatch": false }, { "note": "This is the financing activities section total.", "field": "financingCashFlow", "scale": 1000000, "value": -4940000000, "printed": "(4,940)", "rowIndex": 29, "rowLabel": "Net cash provided by (used in) financing activities", "priorValue": -1135000000, "agentPrinted": "(4,940)", "failedChecks": [], "priorPrinted": "(1,135)", "groundingMismatch": false } ], "statement": "cashflow", "tableIndex": 29, "priorColumn": 1, "currentColumn": 0 }2income statement agent1.80s · 1578 tokens · $0.0002
{ "rows": 32, "retryHint": null, "tableIndex": 26 }{ "figures": [ { "note": "Total revenues is the company-wide revenue line; the separate investment income line is not selected.", "field": "revenue", "scale": 1000000, "value": 402067000000, "printed": "402,067", "rowIndex": 7, "rowLabel": "Total revenues", "priorValue": 372809000000, "agentPrinted": "402,067", "failedChecks": [], "priorPrinted": "372,809", "groundingMismatch": false }, { "note": "This row directly reports operating income.", "field": "operatingIncome", "scale": 1000000, "value": 4660000000, "printed": "4,660", "rowIndex": 16, "rowLabel": "Operating income", "priorValue": 8516000000, "agentPrinted": "4,660", "failedChecks": [], "priorPrinted": "8,516", "groundingMismatch": false }, { "note": "This is net income attributable to CVS Health, excluding noncontrolling interests.", "field": "netIncome", "scale": 1000000, "value": 1768000000, "printed": "1,768", "rowIndex": 25, "rowLabel": "Net income attributable to CVS Health", "priorValue": 4614000000, "agentPrinted": "1,768", "failedChecks": [], "priorPrinted": "4,614", "groundingMismatch": false }, { "note": "This is diluted earnings per share attributable to CVS Health.", "field": "epsDiluted", "scale": 1, "value": 1.39, "printed": "1.39", "rowIndex": 28, "rowLabel": "Diluted", "priorValue": 3.66, "agentPrinted": "1.39", "failedChecks": [], "priorPrinted": "3.66", "groundingMismatch": false } ], "statement": "income", "tableIndex": 26, "priorColumn": 1, "currentColumn": 0 }3balance sheet agent1.91s · 1585 tokens · $0.0002
{ "rows": 45, "retryHint": null, "tableIndex": 28 }{ "figures": [ { "note": "This is the balance sheet’s cash and cash equivalents line.", "field": "cash", "scale": 1000000, "value": 8453000000, "printed": "8,453", "rowIndex": 3, "rowLabel": "Cash and cash equivalents", "priorValue": 8586000000, "agentPrinted": "8,453", "failedChecks": [], "priorPrinted": "8,586", "groundingMismatch": false }, { "note": "This row explicitly reports total assets.", "field": "totalAssets", "scale": 1000000, "value": 253538000000, "printed": "253,538", "rowIndex": 16, "rowLabel": "Total assets", "priorValue": 253215000000, "agentPrinted": "253,538", "failedChecks": [], "priorPrinted": "253,215", "groundingMismatch": false }, { "note": "This is the explicit total liabilities line, not liabilities and equity.", "field": "totalLiabilities", "scale": 1000000, "value": 178156000000, "printed": "178,156", "rowIndex": 33, "rowLabel": "Total liabilities", "priorValue": 177485000000, "agentPrinted": "178,156", "failedChecks": [], "priorPrinted": "177,485", "groundingMismatch": false }, { "note": "This is CVS Health shareholders’ equity, excluding noncontrolling interests.", "field": "totalEquity", "scale": 1000000, "value": 75214000000, "printed": "75,214", "rowIndex": 41, "rowLabel": "Total CVS Health shareholders’ equity", "priorValue": 75560000000, "agentPrinted": "75,214", "failedChecks": [], "priorPrinted": "75,560", "groundingMismatch": false } ], "statement": "balance", "tableIndex": 28, "priorColumn": 1, "currentColumn": 0 }4reconciler (code)0.00s
null
[ { "name": "balance_identity", "detail": "total assets equals total liabilities and equity", "fields": [ "totalAssets" ], "passed": true, "skipped": false, "statement": "balance" }, { "name": "totalEquity_attribution", "detail": "totalEquity excludes noncontrolling interests", "fields": [ "totalEquity" ], "passed": true, "skipped": false, "statement": "balance" }, { "name": "netIncome_before_preferred", "detail": "net income is not the after-preferred-dividends line", "fields": [ "netIncome" ], "passed": true, "skipped": false, "statement": "income" }, { "name": "epsDiluted_total", "detail": "diluted EPS is for total net income", "fields": [ "epsDiluted" ], "passed": true, "skipped": false, "statement": "income" }, { "name": "netIncome_attribution", "detail": "netIncome excludes noncontrolling interests", "fields": [ "netIncome" ], "passed": true, "skipped": false, "statement": "income" }, { "name": "cash_flow_tie", "detail": "operating + investing + financing (+ FX) equals the net change in cash", "fields": [ "operatingCashFlow", "investingCashFlow", "financingCashFlow" ], "passed": true, "skipped": false, "statement": "cashflow" } ]
Income statement
table #26 · current period is figure column 1| 0 | For the Years Ended December 31, | |||
| 1 | In millions, except per share amounts | 2025 | 2024 | 2023 |
| 2 | Revenues: | |||
| 3 | Products | 249,908 | 231,521 | 245,138 |
| 4 | Premiums | 134,751 | 122,896 | 99,192 |
| 5 | Services | 15,175 | 16,239 | 12,293 |
| 6 | Net investment income | 2,233 | 2,153 | 1,153 |
| 7 | Total revenues← Total revenue | 402,067 | 372,809 | 357,776 |
| 8 | Operating costs: | |||
| 9 | Cost of products sold | 221,167 | 206,287 | 217,098 |
| 10 | Health care costs | 125,538 | 115,121 | 86,247 |
| 11 | Operating expenses | 44,977 | 41,706 | 39,832 |
| 12 | Goodwill impairment | 5,725 | - | - |
| 13 | Restructuring charges | - | 1,179 | 507 |
| 14 | Loss on assets held for sale | - | - | 349 |
| 15 | Total operating costs | 397,407 | 364,293 | 344,033 |
| 16 | Operating income← Operating income | 4,660 | 8,516 | 13,743 |
| 17 | Interest expense | (3,119) | (2,958) | (2,658) |
| 18 | Gain on early extinguishment of debt | - | 491 | - |
| 19 | Gain on deconsolidation of subsidiary | 483 | - | - |
| 20 | Other income | 112 | 99 | 88 |
| 21 | Income before income tax provision | 2,136 | 6,148 | 11,173 |
| 22 | Income tax provision | 408 | 1,562 | 2,805 |
| 23 | Net income | 1,728 | 4,586 | 8,368 |
| 24 | Net (income) loss attributable to noncontrolling interests | 40 | 28 | (24) |
| 25 | Net income attributable to CVS Health← Net income attributable to the company | 1,768 | 4,614 | 8,344 |
| 26 | Net income per share attributable to CVS Health: | |||
| 27 | Basic | 1.40 | 3.67 | 6.49 |
| 28 | Diluted← Diluted EPS | 1.39 | 3.66 | 6.47 |
| 29 | Weighted average shares outstanding: | |||
| 30 | Basic | 1,267 | 1,259 | 1,285 |
| 31 | Diluted | 1,271 | 1,262 | 1,290 |
Balance sheet
table #28 · current period is figure column 1| 0 | At December 31, | ||
| 1 | In millions, except per share amounts | 2025 | 2024 |
| 2 | Assets: | ||
| 3 | Cash and cash equivalents← Cash and cash equivalents | 8,453 | 8,586 |
| 4 | Investments | 2,145 | 2,407 |
| 5 | Accounts receivable, net | 39,779 | 36,469 |
| 6 | Inventories | 19,246 | 18,107 |
| 7 | Other current assets | 5,091 | 3,076 |
| 8 | Total current assets | 74,714 | 68,645 |
| 9 | Long-term investments | 32,669 | 28,934 |
| 10 | Property and equipment, net | 13,083 | 12,993 |
| 11 | Operating lease right-of-use assets | 14,973 | 15,944 |
| 12 | Goodwill | 85,478 | 91,272 |
| 13 | Intangible assets, net | 25,508 | 27,323 |
| 14 | Separate accounts assets | 1,994 | 3,311 |
| 15 | Other assets | 5,119 | 4,793 |
| 16 | Total assets← Total assets | 253,538 | 253,215 |
| 17 | Liabilities: | ||
| 18 | Accounts payable | 17,641 | 15,892 |
| 19 | Pharmacy claims and discounts payable | 26,344 | 24,166 |
| 20 | Health care costs payable | 15,399 | 15,064 |
| 21 | Accrued expenses and other current liabilities | 22,387 | 20,810 |
| 22 | Other insurance liabilities | 1,116 | 1,183 |
| 23 | Current portion of operating lease liabilities | 1,737 | 1,751 |
| 24 | Short-term debt | - | 2,119 |
| 25 | Current portion of long-term debt | 4,068 | 3,624 |
| 26 | Total current liabilities | 88,692 | 84,609 |
| 27 | Long-term operating lease liabilities | 13,643 | 14,899 |
| 28 | Long-term debt | 60,502 | 60,527 |
| 29 | Deferred income taxes | 3,832 | 3,806 |
| 30 | Separate accounts liabilities | 1,994 | 3,311 |
| 31 | Other long-term insurance liabilities | 4,716 | 4,902 |
| 32 | Other long-term liabilities | 4,777 | 5,431 |
| 33 | Total liabilities← Total liabilities | 178,156 | 177,485 |
| 34 | Commitments and contingencies (Note 18) | ||
| 35 | Shareholders’ equity: | ||
| 36 | Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding | - | - |
| 37 | Common stock, par value $0.01: 3,200 shares authorized; 1,787 shares issued and 1,271 shares outstanding at December 31, 2025 and 1,778 shares issued and 1,260 shares outstanding at December 31, 2024 and capital surplus | 50,402 | 49,661 |
| 38 | Treasury stock, at cost: 516 and 518 shares at December 31, 2025 and 2024 | (36,790) | (36,818) |
| 39 | Retained earnings | 61,196 | 62,837 |
| 40 | Accumulated other comprehensive income (loss) | 406 | (120) |
| 41 | Total CVS Health shareholders’ equity← Total shareholders' equity attributable to the company | 75,214 | 75,560 |
| 42 | Noncontrolling interests | 168 | 170 |
| 43 | Total shareholders’ equity | 75,382 | 75,730 |
| 44 | Total liabilities and shareholders’ equity | 253,538 | 253,215 |
Cash flow statement
table #29 · current period is figure column 1| 0 | For the Years Ended December 31, | |||
| 1 | In millions | 2025 | 2024 | 2023 |
| 2 | Cash flows from operating activities: | |||
| 3 | Cash receipts from customers | 389,128 | 357,995 | 345,464 |
| 4 | Cash paid for inventory, prescriptions dispensed and health services rendered | (216,493) | (197,726) | (208,848) |
| 5 | Insurance benefits paid | (121,238) | (109,464) | (84,097) |
| 6 | Cash paid to other suppliers and employees | (37,570) | (38,821) | (34,735) |
| 7 | Interest and investment income received | 1,969 | 1,735 | 1,584 |
| 8 | Interest paid | (2,991) | (2,909) | (2,418) |
| 9 | Income taxes paid | (2,166) | (1,703) | (3,524) |
| 10 | Net cash provided by operating activities← Net cash from operating activities | 10,639 | 9,107 | 13,426 |
| 11 | Cash flows from investing activities: | |||
| 12 | Proceeds from sales and maturities of investments | 12,383 | 10,353 | 7,729 |
| 13 | Purchases of investments | (15,012) | (15,191) | (9,043) |
| 14 | Purchases of property and equipment | (2,832) | (2,781) | (3,031) |
| 15 | Acquisitions (net of cash and restricted cash acquired) | (436) | (95) | (16,612) |
| 16 | Other | 26 | 101 | 68 |
| 17 | Net cash used in investing activities← Net cash from investing activities | (5,871) | (7,613) | (20,889) |
| 18 | Cash flows from financing activities: | |||
| 19 | Commercial paper borrowings (repayments), net | (2,119) | 1,919 | 200 |
| 20 | Proceeds from issuance of short-term loan | - | - | 5,000 |
| 21 | Repayment of short-term loan | - | - | (5,000) |
| 22 | Proceeds from issuance of long-term debt | 3,969 | 7,913 | 10,898 |
| 23 | Repayments of long-term debt | (3,629) | (4,773) | (3,166) |
| 24 | Repurchase of common stock | - | (3,023) | (2,012) |
| 25 | Dividends paid | (3,397) | (3,373) | (3,132) |
| 26 | Proceeds from exercise of stock options | 394 | 361 | 277 |
| 27 | Payments for taxes related to net share settlement of equity awards | (158) | (185) | (181) |
| 28 | Other | - | 26 | (201) |
| 29 | Net cash provided by (used in) financing activities← Net cash from financing activities | (4,940) | (1,135) | 2,683 |
| 30 | Net increase (decrease) in cash, cash equivalents and restricted cash | (172) | 359 | (4,780) |
| 31 | Cash, cash equivalents and restricted cash at the beginning of the period | 8,884 | 8,525 | 13,305 |
| 32 | Cash, cash equivalents and restricted cash at the end of the period | 8,712 | 8,884 | 8,525 |